Please ensure Javascript is enabled for purposes of website accessibility

10 Most Profitable Companies in Healthcare

By Keith Speights – May 7, 2015 at 8:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Like super-profitable companies? These healthcare stocks might be just what the doctor ordered.


$3 trillion. That's a staggering figure. And it's roughly how much is spent on healthcare each year in the U.S. alone. With that much money changing hands, there are plenty of companies making lots of profit. But which are the most profitable?

The best metric to use in answering this question is profit margin -- the amount of profit made as a percent of revenue. Below are the 10 most profitable healthcare companies based on profit margin with market caps of at least $200 million. 

Company Profit Margin
AMAG Pharmaceuticals (AMAG) 109.19%
PDL BioPharma (PDLI) 66.11%
Enanta Pharmaceuticals (ENTA 2.02%) 65.80%
NewLink Genetics Corporation (NLNK) 59.60%
Shire plc (NASDAQ: SHPG) 56.55%
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)  52.31%
ANI Pharmaceuticals (ANIP 5.00%) 51.36%
Gilead Sciences (GILD -0.68%) 48.62%
Vanda Pharmaceuticals (VNDA 2.56%) 40.25%

Birds of a feather?
Several of the 10 most profitable healthcare companies have things in common. For example, seven of the companies listed are biotechs. The three exceptions to this -- AMAG, POZEN and Taro -- are pharmaceutical companies that don't fit under the biotech umbrella. Healthcare includes hospitals, medical device makers, software companies, insurers, and others, but none of them made the top 10 for profitability.

When it comes to profitability, it appears that small is big. Seven on the list have market caps well below the $3 billion, qualifying them as small cap stocks. Taro's market cap is the least of the three outliers at a little over $6 billion. Shire's market cap stands at nearly $48 billion. Meanwhile, Gilead Sciences is worth more than all other nine companies combined -- with a market cap topping $157 billion.

Source: Gilead Sciences

There's another perhaps counter-intuitive similarity among most of the top 10: relatively low valuation. Only one company on the list carries a trailing 12-month earnings multiple that is higher than that of the S&P 500 index -- ANI Pharmaceuticals, which has a P/E of 24. Eight of the companies claim earnings multiples below 15.

Of course, investors often look more closely at valuation levels based on future earnings estimates. Several of the most profitable healthcare companies look relatively inexpensive on that front, also. Three have current share prices that are less than 10 times their forward earnings estimates: AMAG, Gilead and PDL BioPharma. Meanwhile, Enanta, POZEN and Taro all have forward P/E ratios below 15.

Profitable picks?
Which of these highly profitable companies could also be the most profitable picks for investors? That's a tough question, because those disclaimers that every financial manager makes about "past performance may not be indicative of future results" can also apply to individual stocks.

PDL BioPharma, for example, makes its money primarily through royalties from drugs that it has licensed to other companies. 71% of its revenue in 2014 came from drugs licensed to Genentech. However, that revenue dries up after the first quarter of 2016. While PDL is working hard to forge deals to make up the gap, there is considerable risk that the company won't be as profitable in the future.

I also suspect that AMAG Pharmaceuticals could be in for some challenges. Nearly 70% of its 2014 sales stemmed from iron-replacement drug Feraheme. In January, though, Rockwell Medical gained FDA approval for Triferic -- an iron-replacement drug that isn't delivered intravenously. Triferic could be a game-changer in ways that make winning more difficult for AMAG.

Source: Taro Pharmaceuticals 

Several of these companies do appear to have a good shot at continued success, though. My top pick is Gilead Sciences. Gilead has several things going for it. The biotech's hepatitis C drugs are raking in billions while providing a cure for the disease for many. Gilead also dominates the HIV drug market. The company has several up-and-coming drugs in other indications, too. And having a cash stockpile of more than $14 billion to reward shareholders through share buybacks and dividend payouts plus invest in new drugs is a huge plus.

Taro Pharmaceuticals is another one that investors might want to check out. The Israel-based company makes most of its revenue from generic drugs, especially in topical creams, ointments, and gels. Taro has seen steady revenue and earnings increases for the last several years. With lots of merger and acquisition activity among generic drugmakers recently, the company could find itself a buyout target down the road.

Keith Speights owns shares of Gilead Sciences. The Motley Fool also recommends and owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.64 (-0.68%) $0.43
ANI Pharmaceuticals, Inc. Stock Quote
ANI Pharmaceuticals, Inc.
$33.21 (5.00%) $1.58
PDL BioPharma, Inc. Stock Quote
PDL BioPharma, Inc.
Taro Pharmaceutical Industries Ltd. Stock Quote
Taro Pharmaceutical Industries Ltd.
$29.95 (4.21%) $1.21
AMAG Pharmaceuticals, Inc. Stock Quote
AMAG Pharmaceuticals, Inc.
Vanda Pharmaceuticals Inc. Stock Quote
Vanda Pharmaceuticals Inc.
$10.02 (2.56%) $0.25
NewLink Genetics Corporation Stock Quote
NewLink Genetics Corporation
Enanta Pharmaceuticals, Inc. Stock Quote
Enanta Pharmaceuticals, Inc.
$53.48 (2.02%) $1.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.